Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Polyprotein cleavage mechanism of SARS CoV M\text{pro} and chemical modification of the octapeptide

Qi-Shi Dua,b, Shu-Qing Wanga, Yu Zha, Dong-Qing Wei\textsuperscript{b,c}, Hong Guod, Suzanne Sirois\textsuperscript{b}, Kuo-Chen Chou\textsuperscript{a,e,f,*}

\textsuperscript{a} Tianjin Normal University and Tianjin Institute of Bioinformatics and Drug Discovery (TIBDD), Tianjin 300074, China
\textsuperscript{b} Institut Technologique de Montreal, Suite 168, 5255 Boul. Decarie, Montreal, Que., Canada H3W 3C1
\textsuperscript{c} Center For Research in Molecular Modeling (CERMM), Concordia University, Montreal, Canada
\textsuperscript{d} University of Tennessee, Department of Biochemistry, Cell and Molecular Biology, Knoxville, TN 37996-0840, USA
\textsuperscript{e} Institute of Image Processing and Pattern Recognition, Shanghai Jiaotong University, Shanghai 200030, China
\textsuperscript{f} Gordon Life Science Institute, San Diego, CA 92130, USA

Received 1 May 2004; received in revised form 18 June 2004; accepted 22 June 2004
Available online 31 July 2004

Abstract

The cleavage mechanism of severe acute respiratory syndrome (SARS) coronavirus main proteinase (M\textsuperscript{pro} or 3CL\textsuperscript{pro}) for the octapeptide AVLQSGFR is studied using molecular mechanics (MM) and quantum mechanics (QM). The catalytic dyad His-41 and Cys-145 in the active pocket between domain I and II seem to polarize the $\pi$-electron density of the peptide bond between Gln and Ser in the octapeptide, leading to an increase of positive charge on C(\textsuperscript{CO}) of Gln and negative charge on N(\textsuperscript{NH}) of Ser. The possibility of enhancing the chemical bond between Gln and Ser based on the “distorted key” theory [Anal. Biochem. 233 (1996) 1] is examined. The scissile peptide bond between Gln and Ser is found to be solidified through “hybrid peptide bond” by changing the carbonyl group CO of Gln to CH\textsubscript{2} or CF\textsubscript{2}. This leads to a break of the $\pi$-bond system for the peptide bond, making the octapeptide (AVLQSGFR) a “distorted key” and a potential starting system for the design of anti SARS drugs.

Keywords: SARS; Coronavirus main proteinase; Inhibitor; Distorted key theory; Drug design; Octapeptide; KZ7088

1. Introduction

Spreading of severe acute respiratory syndrome (SARS) [22,26,27,31] in Asia, North America and several countries in Europe prompted an unprecedented global effort to fight the disease. Researchers have identified crucial proteins of SARS-coronavirus and thousands of compounds are being screened in an effort to find new drugs [7,20,32]. Anand et al. [7] described a homology model of SARS coronavirus main proteinase (M\textsuperscript{pro} or 3CL\textsuperscript{pro}) based on the experimental M\textsuperscript{pro} structures of human coronavirus (HCoV) and porcine transmissible gastroenteritis virus (TGEV) complex. Recently, the crystal structures of SARS CoV M\textsuperscript{pro} at different pH values were reported by Yang et al. [34]. The X-ray structures revealed some differences with the homology model obtained earlier [7]. However, experimental structure of SARS CoV M\textsuperscript{pro} folds in an arrangement that is similar to the HCoV and TGEV M\textsuperscript{pro} structures, and both homology model and experimental structure have a His–Cys catalytic dyad between domains I and II [34]. The structures of the three coronavirus main proteinases reveal remarkable degree of conservation on the substrate-binding sites and form the structure basis for rational drug design [7,20].
At the same time, structure-based drug design has been progressing based on the molecular structure of SARS-CoV M\textsuperscript{pro} [20]. AG7088 suggested by Anand et al. [7] could well serve as a starting point to design efficient inhibitors for SARS CoV M\textsuperscript{pro}. AG7088 is a peptide inhibitor designed based on the structure of HCoV M\textsuperscript{pro} and is being clinically tested by Pfizer for the treatment of the human common cold. Chou et al. [20] have found some deficiency of AG7088 for binding to SARS CoV M\textsuperscript{pro} and suggested to use its derivative KZ7088 that could form better interactions with the active pocket of SARS CoV M\textsuperscript{pro}. Chou et al. also proposed an octapeptide inhibitor NH\textsubscript{2}−AVLQSGFR−COOH (the cleavage site is indicated by ↓) based on molecular modelling. This suggestion was supported by the recent work of Yang et al. [34]. In their structural determination, these authors used a decade peptide NH\textsubscript{2}−TSAVLQSGFR−COOH, which is quite similar to the octapeptide NH\textsubscript{2}−AVLQSGFR−COOH. According to a very recent report by Gan et al. [23], the octapeptide originally proposed by Chou et al. [20] has been synthesized and tested as the most active in inhibiting replication of the SARS coronavirus compared with other compounds reported. Moreover, it has been found that the octapeptide had no toxicity in vivo under the physiological concentration [23]. That a peptide is cleavable by a protease means that there is good binding between ligand and receptor on the active region of protease and that the peptide has a scissile bond to be cleaved (see, e.g., [13]) and a comprehensive review [12]. However, one needs to make some further chemical modification for the octapeptide in order to stabilize its inhibition power to SARS CoV M\textsuperscript{pro} and make it become an effective drug. This may be realized based on the "distorted key" theory [12,13]. To reach such a goal, a detailed understanding of the cleavage mechanism of the octapeptide by SARS CoV M\textsuperscript{pro} as well as the 3D structure of the enzyme is essential. Similar strategies have been used to investigate Cdk5–Nc5a complex [19,36], apoptosis proteins [10,11,15,17], and beta-secretase zymogen [14]. Many useful insights have been gained through these studies. Accordingly, it is expected that the present study may also provide useful insights for the development of anti SARS drug.

2. Theory and method

The protease-susceptible sites in a given protein or peptide usually extend to an octapeptide region [12,13]. The corresponding amino acid residues are sequentially symbolized by eight subsites R\textsubscript{1}, R\textsubscript{2}, R\textsubscript{3}, R\textsubscript{4}, R\textsubscript{1}', R\textsubscript{2}', R\textsubscript{3}', R\textsubscript{4}' and the eight combination positions of protease are noted by S\textsubscript{1}, S\textsubscript{2}, S\textsubscript{3}, S\textsubscript{4}, S\textsubscript{1}', S\textsubscript{2}', S\textsubscript{3}', S\textsubscript{4}' (see, e.g., [8,9] as well as Fig. 3 of [12]). Occasionally, the susceptible sites in some proteins may contain one subsite less or more [13], however, eight amino acid residues are the most common cases. Although the protein being cleaved contains much more than eight amino acid residues, usually only the segment of an octapeptide fits in the active site region of a protease. Therefore, our research will focus on the cleavability of an octapeptide.

As shown in Fig. 1a, the combination of a thin line and a dashed line is used to represent the conjugate π property in peptide bond. In Fig. 1b, however, the scissile peptide bond is replaced by a strong "hybrid peptide bond" between R\textsubscript{1} and R\textsubscript{1}'. After chemical modification, the scissile peptide bond changes to a strong "hybrid peptide bond" and the cleavage is difficult. Adapted from Chou [12] with permission.
Fig. 2. The energy-refined docked structure of the octapeptide NH$_2$A VLQSGFR COOH with SARS coronavirus main protease (SARS CoV M$^{\text{pro}}$).

3. Calculation results

The docking operation of the octapeptide AVLQSGFR to SARS CoV M$^{\text{pro}}$ was performed based on the homology structure [7,20] using MOE (molecular operating environment) program package [28]. Twenty-five docking structures were obtained, and the one with the most optimal docking score was used for further energy minimization. Fig. 2 shows the energy-refined docked structure obtained by the aforementioned step 1. In contrast to the common serine proteases that have a Ser–His–Asp catalytic triad, SARS CoV M$^{\text{pro}}$ has a His–Cys catalytic dyad (His-41 and Cys-145), which is similar to TGEV M$^{\text{pro}}$ (His-41 and Cys-144) and HCoV M$^{\text{pro}}$ (His-41 and Cys-144) [7,29]. According to Chou et al. [20], the catalytic active region is located within the pocket between domain I and II of SARS coronavirus main protease that contains the following 23 amino acid residues: Cys-22, Gly-23, Thr-24, Thr-25, Leu-27, His-41, Val-42, Cys-44, Thr-45, Ala-46, Glu-47, Asp-48, Met-49, Leu-50, Asn-51, Pro-52, Tyr-54, Cys-145, His-146, Met-165, Asp-187, Arg-188, and Gln-189. Fig. 3a shows the location of catalytic dyad His-41 and Cys-145 in SARS CoV M$^{\text{pro}}$. The active cleft of SARS CoV M$^{\text{pro}}$ can well accommodates the octapeptide, and the ligand binds to the receptor through six hydrogen bonds (Fig. 3b), fully in consistent with the results reported by Chou et al. [20].

In order to study the influence of SARS CoV M$^{\text{pro}}$ on chemical bonds of the octapeptide, we considered a small region from the catalytic cleft surrounding the octapeptide, as shown in Fig. 3b. The catalytic dyad His-41 and Cys-145 are in the front of peptide bond Gln–Ser on the subsites R$_1$ and R$_2$. The polar hydrogen H$_2$ on N$_2$ in imidazole group of His-41 points to the peptide bond Gln-Ser and has large influence in the active region.

Fig. 3. (a) The catalytic dyad His-41 and Cys-145 are located in the active cleft between domain I and domain II of SARS CoV M$^{\text{pro}}$. (b) The hydrogen bonds between NH$_2$ AVLQSGFR COOH and the surrounding amino acid residues of the enzyme.
Electrostatic interaction plays the dominant role in ligand–receptor combination and must be taken into consideration during the quantum mechanical calculations for the influence of SARS CoV Mpro to the chemical bonds of the octapeptide. For this purpose, we divide the amino acid residues in the active cleft between domain I and II of SARS CoV Mpro into six segments and compute the atomic charges using ab initio quantum mechanics separately (Fig. 4). The 62 amino acid residues in the six segments are listed in Table 1. After deducting the overlap atoms, there are a total of 953 atomic background charges, including all atoms in catalytic cleft.

In Table 2, we list Mulliken atomic charges $q^{\text{Mull}}$ and electrostatic potential equivalent charges $q^{\text{ESP}}$, which are obtained by fitting atomic charges to the electrostatic potential at the van der Waals surface. The atomic charges from semi-empirical method AM1 are quite different from the results by ab initio HF/6-31G* calculations [25], especially $q^{\text{ESP}}$ of AM1 are not reasonable. Because $q^{\text{ESP}}$ reproduces quantum mechanical electrostatic potential on molecular surface, in this research, we use $q^{\text{ESP}}$ from HF/6-31G* calculations to illustrate our points. It can be seen from Table 2 that the two polar hydrogen atoms on imidazole group have large atomic charges $q^{\text{ESP}}$. The atomic charge (0.4201) of polar hydrogen H$_2$/H$_{9255}$ is a little smaller than the atomic charge (0.4288) of proton H$_{\delta^1}$/H$_{9254}$ on nitrogen N$_1$ and is close to the peptide bond Gln–Ser on subsites R$_1$ and R$_{1}'$. The polar hydrogen H$_2$/H$_{9255}$ attracts the $\pi$-electron density from peptide bond Gln–Ser so as to weaken this chemical bond.

We calculate the cleavage reaction energy from the octapeptide AVLQSGFR to two tetrapeptides AVLQ and SGFR using ab initio HF/6-31G* in the gaseous phase. The molecular energies of the octapeptide and two tetrapeptides are shown in Table 3 and the hydrolyzing reaction energy is 110.8 kJ/mol.

### 4. Chemical modification of the octapeptide

The peptide bond is considered as a pseudo $\pi$-bond, i.e., a partial $\pi$-bond consisting of three atoms and four electrons [33]. Table 4 shows the atomic coordinates of the six atoms on
the two ends of peptide bond (Gln<CO>≡N<Hi>Ser). The X-coordinates of the six atoms are almost the same. The carbonyl group CO of glutamine and the nitrogen atom N(NH) of Serine form a $\pi$ bond. The catalytic dyad His-41 and Cys-145 in the active pocket between domain I and II attracts the two ends of peptide bond Glu-Ser, causing the increase of positive charge on C(CO) of glutamine and negative charge on N(NH) of serine, and that the electrophilic proton H$^+$ attacks N(NH) of serine and nucleophilic OH$^-$ attacks C(CO) of glutamine, respectively. The catalytic functional group is the imidazole ring of His-41 and plays the acid-base catalytic role. The $\pi$K value of imidazole group of histidine is 6.0, the concentration of [H$^+$] is the same as in water, and hence, His-41 serves as a good proton provider in life condition [33].

$E_\text{calc}(\text{HF/6-31G}^\ast)$

Table 2

Atomic charges of amino acid His-41 in SARS CoV M$^{\text{MP}_{\text{esp}}}$

| Atom | AM1 (q$^{\text{esp}}$) | AM1 (q$^{\text{esp}}$) | HF6-31G (q$^{\text{esp}}$) | HF6-31G (q$^{\text{esp}}$) |
|------|----------------------|----------------------|----------------------|----------------------|
| N    | −0.5403              | −5.5624              | −0.9145              | −0.9637              |
| H(N) | 0.3609               | 0.8209               | 0.3991               | 0.3419               |
| C    | −0.0528              | 6.1962               | −0.0083              | 0.6296               |
| H$_2$| 0.2347               | −1.2792              | 0.3013               | 0.0600               |
| C    | 0.3710               | −0.8132              | 0.8128               | 0.5624               |
| O    | −0.3964              | −0.5648              | −0.6464              | −0.6346              |
| C$_2$| −0.1888              | −4.6016              | −0.3596              | −0.2660              |
| H$_2$| 0.1921               | 1.1542               | 0.2351               | 0.0832               |
| H$_2$| 0.1426               | 0.6820               | 0.1807               | 0.0959               |
| C$_2$| −0.0833              | 1.2703               | 0.2802               | 0.2473               |
| H$_2$| −0.2976              | −0.1343              | −0.9053              | −0.4730              |
| H$_2$| 0.3777               | 0.8715               | 0.4483               | 0.4288               |
| C$_2$| −0.0778              | −0.6847              | 0.1800               | 0.0619               |
| H$_2$| 0.3617               | 0.1458               | 0.3704               | 0.1440               |
| C$_2$| 0.0330               | −2.4836              | 0.5501               | 0.2165               |
| H$_2$| 0.3607               | 1.7427               | 0.3516               | 0.2269               |
| N$_2$| −0.2724              | 1.0889               | −0.8636              | −0.3348              |
| H$_2$| 0.4199               | −0.0400              | 0.4877               | 0.4201               |

Table 3

Chemical reaction energy of the octapeptide cleavage in gaseous phase

| Octapeptide P8 (bactere) | −2990.6247 |
|-------------------------|-----------|
| Octapeptide P8 (bactere) | −1461.5333 |
| Quatpeptide 2 P8 (bactere) | −1605.2700 |
| Water (bactere)          | −76.0070  |
| Energy (kJ/mol)          | 130.0     |

$^a$ 1 Hartree = 2625.5 kJ/mol.

Fig. 4 is the electron density counter map of peptide bond Glu–Ser in gaseous phase on the $\pi$–plane consisting of C and O in carbonyl group (C=O of Gln and N(NH) of Ser). The electron density counters surrounding atom N(NH) and C(CO) form two triangles like $sp^2$ hybrid orbits, therefore, the $2p_x$ orbit of the three atoms, which are perpendicular to the plane, form a $\pi^*$ bond system. In Table 4, we list the atomic charges of the six atoms on both sides of peptide bond Gln–Ser obtained from ab initio HF6-31G$^*$ calculations in gaseous phase with the background charges of SARS CoV M$^{\text{MP}_{\text{esp}}}$.

Table 4

Atomic charges and coordinates of six atoms on both sides of peptide bond Gln–Ser in the octapeptide

| Glutamine side | Serine side |
|----------------|-------------|
| C$_9$          | Gln(CO)     | O(CO)     | H$_{Gln}$ |
| q$^{\text{esp}}$(gas) | 0.0247     | 0.7706    | −6.6743   | −0.0128 | −0.8343 | 0.4120 |
| q$^{\text{esp}}$(MP$^*$) | 0.0805     | 0.8074    | −0.6545   | −0.2073 | −0.8689 | 0.4212 |
| X (Å)          | −34.348     | −34.698   | −34.813   | −34.916 | −34.878 | −34.732 |
| Y (Å)          | 14.691      | 15.100    | 16.316    | 14.399  | 14.156  | 13.185  |
| Z (Å)          | −2.681      | −4.041    | −4.254    | −6.348  | −4.998  | −4.769  |

$^a$  Atomic charges in the gaseous phase.

$^b$ Atomic charges in SARS CoV M$^{\text{MP}_{\text{esp}}}$ background charges.
Fig. 5. The contour map of electron density difference of peptide bond Gln–Ser in the octapeptide AVLQSGFR obtained by subtracting the electronic density in gaseous phase from the electronic density in background charges of SARS CoV Mpro.

Table 5
Atomic charges of the six atoms on two sides of peptide bond Gln–Ser after chemical modification

|        | Glutamine side | Serine side |
|--------|----------------|-------------|
| C      | C(CH2)         | H(CH2)      |
| qESP (gas) | 0.0578         | −0.1040     |
| qESP (Mpro) | 0.1127         | −0.1211     |
| H      | N(NH)          | H(NH)       |
| qESP (gas) | −0.0081        | −0.7690     |
| qESP (Mpro) | −0.2164        | −0.7771     |

* Atomic charges in gaseous phase.
* Atomic charges in SARS CoV Mpro background charges.

in SARS CoV Mpro background charges than in gaseous phase and the dashed thin lines show the areas where the electron densities are smaller in protease background charges than in gaseous phase. We find that along the peptide bond between (Gln)C–N(Ser) the electron densities increase on N(Ser) side and decrease on (Gln)C side. This change is favorable for the nucleophilic attack of anion OH− on (Gln)C and electrophilic attack of cation H+ on N(Ser).

SARS CoV Mpro has a very high selectivity[7,34], and in the polyprotein cleavage sites, the subsite R1 is invariably occupied by Gln. A simple routine way to make the octapeptide AVLQSGFR to an effective inhibitor for SARS CoV Mpro and an effective drug candidate against SARS. Here we show the possibility of chemical modification to the octapeptide AVLQSGFR through computational modeling.

Table 5 lists atomic charges of the six atoms on the both sides of hybrid peptide bond Gln–Ser after changing carboxyl group CO of Gln to CH2 group. Comparing with Table 4, we find that the carbon atom in CH2 group of hybrid peptide bond turns to be negative −0.1040 from positive charge 0.7706 in CO group (see Table 4), and hence, the nucleophilic attack by OH− is impossible. On the other hand, the negative charge of N(NH) of the Ser side decreases from −0.8689 to −0.7771 in Table 4, and hence, the electrophilic attack by H+ is more difficult. The third row in Table 5 is the atomic charges in the background...
Ala–Val–Leu–Gln–Ser–Gly–Phe–COOH is the first one designed based on the molecular structure of SARS CoV Mpro, we need two types of sets: protease[1–6,12,16] and vectorized sequence-coupled algorithm[13], and some other algorithms, such as discriminant function algorithm[12,18], or a "distorted key"[12]. Any statistical prediction methods depend on training sets and the number of possible octapeptides is huge (20^8 = 2.60 × 10^16) [12,13]. A cleavable octapeptide could be found by using some existing prediction algorithms, such as discriminant function algorithm[12,18], vectorized sequence-coupled algorithm [13], and some other relevant algorithms [8,9,35]. These prediction methods have been successfully applied to help the inhibitor design for HIV protease [1–6,12,16].

Any statistical prediction methods depend on training sets of known samples [21,37]. For the prediction of cleavable octapeptides for SARS CoV Mpro, we need two types of sets: one is positive training set consisting of cleavable octapeptides and other is negative training set consisting only of uncleavable octapeptides. The building of negative training set is easy. For example, if we know a protein consisting of 129 amino acid residues is not cleavable by SARS CoV Mpro, we can get 129 = 129 − 7 non cleavable octapeptides immediately. However, building a positive training set needs some experiments. Computer simulation and molecular modeling are a good ways to accelerate this procedure. The method and conclusion from this research is helpful for this purpose.

Acknowledgements

This work is supported by grants from the Tianjin Commission of Sciences and Technology under the contract number 023618211 and the Chinese National Science Foundation under the contract no. 20373048.

References

[1] Althaus IW, Chou JJ, Gonzales AJ, Diebel MR, Chou KC, Kezdy FJ. Kinetic studies with the nonnucleoside HIV-1 reverse transcriptase inhibitor U-84014E. Biochemistry 1993;32:6548–54.

[2] Althaus IW, Chou JJ, Gonzales AJ, Diebel MR, Chou KC, Kezdy FJ, et al. Steady-state kinetic studies with the non-nucleoside HIV-1 reverse transcriptase inhibitor U-84016E. J Biol Chem 1994;269:24–24.

[3] Althaus IW, Chou JJ, Gonzales AJ, Diebel MR, Chou KC, Kezdy FJ, et al. Steady-state kinetic studies with the non-nucleoside HIV-1 reverse transcriptase inhibitor U-86152E. Biochem Pharmacol 1994;47:2017–28.

[4] Althaus IW, Chou KC, Franks KM, Diebel MR, Kezdy FJ, Romero DL, et al. The benzylihydroxypyridazine U-31355 is a potent inhibitor of HIV-1 reverse transcriptase. Biochem Pharmacol 1996;51:743–50.

[5] Anand K, Ziebuhr J, Wadhwani P, Musters JR, Hilgenfeld R. Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs. Science 2003;300:1763–7.

[6] Chou J. Formulation for correlating properties of peptides and its application to predicting human immunodeficiency virus protease-cleavable sites in proteins. Biopolymers 1993;33:1405–14.

[7] Chou J. Predicting cleavability of peptide sequences by HIV protease via correlation-angle approach. J Protein Chem 1993;12:291–302.

[8] Chou J, Li H, Salvesen GS, Yuan J, Wawer G. Solution structure of BID, an intracellular amplifier of apoptotic signaling. Cell 1999;96:615–24.

[9] Chou J, Matsuo H, Duan H, Wagner G. Solution structure of the beta-secretase zymogen. Biochem Biophys Res Commun 2001;289:245–48.

[10] Chou J, Lowe WJ. Prediction of the tertiary structure of the beta-secretase zymogen. Biochim Biophys Acta 2002;1581:702–8.

[11] Chou KC, Jonas D, Henriksen RL. Prediction of the tertiary structure and substrate binding site of caspase-8. FEBS Lett 1997;419:49–54.

[12] Chou KC, Kezdy FJ, Reusser F. Prediction of the tertiary structure of caspase-8/inhibitor complex. FEBS Lett 1997;419:49–54.

[13] Chou KC, Tomasselli AG, Henriksen RL. Prediction of the tertiary structure of a caspase-9/inhibitor complex. FEBS Lett 2000;470:249–56.

[14] Chou KC, Eyferth J, Reusser F. Determination of the tertiary structure of the caspase-9/inhibitor complex. FEBS Lett 2000;479:171–80.

[15] Chou KC, Tomasselli AL, Reardon DM, Henriksen RL. Predicting HIV protease cleavage sites in proteins by a discriminant function method. Proteins: Struct Funct Genet 1998;31:107–18.

[16] Chou KC, Tomasselli AL, Reardon DM, Henriksen RL. A Model of the complex between cystine-dependent kinase (CkII) and the activation domain of neuronal Cdk5 activator. Biochem Biophys Res Commun 1999;240:426–8.

[17] Chou KC, Weis JD, Zhong WZ. Binding mechanism of coronavirus main protease with ligands and its implication to drug design against SARS (erratum: ibid. vol.310, 675). Biochem Biophys Res Commun 2003;308:148–51.

[18] Chou KC, Zhang CT. Review. Prediction of protein structural classes. Crit Rev Biochem Mol Biol 1993;28:375–399.
[22] Drosten C, Günther S, Preiser W, van der Werf S, Brodt HR, Becker S, et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med 2003;348:1967–76.

[23] Gan YR, Huang YD, Huang H. Synthesis and biological evaluation of a novel SARS CoV Mpro inhibitor. Personal Communication.

[24] Foreman RB, Frisch A. Exploring chemistry with electronic structure methods: a guide to using Gaussian. Gaussian Inc., Pittsburgh, PA; 1993.

[25] Hehre WJ, Radom L, Schleyer PR, Pople JA. Ab initio molecular orbital theory. New York: Wiley; 1986, chapter 2.

[26] Ksiazek TG, Erdman D, Goldsmith CS, Zaki SR, Peret T, Emery S, et al. A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med 2003;348:1953–66.

[27] Miura HS, Nakagaki K, Taguchi F. N-terminal domain of the murine coronavirus receptor CEACAM1 is responsible for fusogenic activation and conformational changes of the spike protein. J Virol 2004;78:216–23.

[28] Molecular operating environment (MOE). Montreal, Quebec, Canada: Chemical Computing Group; 2003.

[29] Qin E, Zhu Q, Yu M, Fan B, Chang G, Si B, Yang B, Peng W, Jiang T, Liu B, et al. SARS coronavirus B003 isolate genome sequence. Submitted APR-2003 to the EMBL GenBank DDBJ databases 2003.

[30] Schulz GE, Schummer RH. Principles of protein structure. New York: Springer-Verlag; 1985, Chapter 2.

[31] Shuttar DJ. Severe acute respiratory syndrome and influenza virus infections from southern China. Am J Respir Crit Care Med 2003;168:1416–20.

[32] Sirois S, Wei DQ, Du Q, Chou KC. Virtual screening for SARS CoV protease based on KZ788 pharmacophore points. J Chem Inf Comput Sci 2004;44:1111–22.

[33] Stryer L. Biochemistry. 3rd ed. New York: W.H. Freeman and Company; 1988.

[34] Yang H, Yang M, Dong Y, Liu Y, Lou Z, Zhou Z, et al. The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor. Proc Natl Acad Sci USA 2003;100:1190–5.

[35] Zhang CT, Chou KC. An alternate-subsite-coupled model for predicting HIV protease cleavage sites in proteins. Protein Eng 1993;7:65–73.

[36] Zhang J, Luo CH, Chou KC, Johnson GVW. Identification of the N-terminal functional domains of Cdk5 by molecular truncation and computer modeling. Proteins: Struct Funct Genet 2002;48:447–53.

[37] Zhou GP, Doctor K. Subcellular location prediction of apoptosis proteins. Proteins: Struct Funct Genet 2003;50:44–8.